APR 102

Drug Profile

APR 102

Alternative Names: SP-SAP; Substance P-Saporin

Latest Information Update: 12 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Advanced Pain Therapeutics LLC
  • Developer Advanced Pain Remedies; University of Texas Southwestern Medical Center
  • Class Analgesics; Anti-inflammatories; Biological proteins; Biological toxins; Drug conjugates; Immunotoxins; Neuropeptides; Peptides; Proteins
  • Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 01 Jan 2014 Phase-I clinical trials in Pain in USA (Intrathecal)
  • 10 Jan 2011 Advanced Pain Therapeutics is now called Advanced Pain Remedies
  • 10 Jan 2011 Advanced Targeting Systems receives award from the US National Cancer Institute (NCI) for SP SAP development in Cancer pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top